Post-transplant diabetes mellitus (PTDM) is a frequent consequence of solid organ
transplantation. PTDM has been associated with greater mortality and increased infections …

Background Women with type 2 diabetes (T2D) are less likely to reach the goals for
hemoglobin A1c compared with men, and have higher all-cause mortality. The risk of …

OBJECTIVE Renal impairment in type 2 diabetes limits available glucose-lowering treatment
options. This trial was conducted to establish the efficacy and safety of liraglutide as an add …

The sulphonylureas act by triggering insulin release from the pancreatic β cell. A specific site
on the adenosine triphosphate (ATP)-sensitive potassium channels is occupied by …

Diabetes mellitus is recognized as a leading cause of chronic kidney disease (CKD) and
end‐stage renal disease (ESRD) in the United States. There is a vast array of medications …

OBJECTIVE Patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease have
an increased risk of micro-and macrovascular disease, but limited options for …

This review mainly focuses on metformin, and considers oral antidiabetic therapy in kidney
transplant patients and the potential benefits and risks of antidiabetic agents other than …

New-onset diabetes after transplantation (NODAT) is a serious complication after kidney
transplantation, but therapeutic strategies remain underexplored. Dipeptidyl peptidase-4 …

Currently available oral agents for the treatment of type 2 diabetes mellitus include a variety
of compounds from 5 different pharmacologic classes with differing mechanisms of action …

In patients with Type 2 diabetes, the appropriate intensity of glucose control is determined by
age, life expectancy, and the presence of concomitant disease. Geriatric patients are …